Global Access to CAR T-Cell Therapy

Explore the gap in access to CAR T-cell therapy worldwide, the impact of high costs, and why location affects cancer treatment options.

CAR T-cell therapy has been an important advance in blood cancer care since the first CAR-T approval in 2017. This therapy has helped many people who tried numerous treatments and still struggled to have their disease controlled. But there is still a gap in real-world access.

In the United States, barriers to CAR-T include the cost of the treatment and distance to a treatment center. But what about globally? In this article we share insights from a recent study that looks at how available this therapy actually is around the world. Discover why some countries have it while others do not, the high costs involved, and what this means for patients waiting for a cure.

Why CAR T-cell therapy access matters

The gap between scientific discovery and real-world use is growing. While scientists are finding new ways to treat cancer, the health care systems used to deliver those treatments are moving more slowly. This creates a situation where a life-saving medicine exists, but a patient's ability to get it depends entirely on where they live.

If a country does not provide public funding for the therapy, only a very small group of people can afford it. This leads to "clinical inequity." This is a term for when some people receive better care than others based on their resources or location.

Identifying the barriers to CAR-T is key for healthcare professionals and industries 

To truly understand the real access many people have to CAR-T, healthcare professionals need to know the difficulties patients still face in the medical system: 

• Travel distance: Many patients live far from the specialized centers that offer this care.
• Center capacity: There are limits on how many patients a single hospital can treat at one time.
• Out-of-pocket costs: Even if the medicine is covered by insurance, extra costs for travel and stay can become too high for many families.
• Local delays: Rules governing hospital accreditation and administrative procedures can create long wait times.

The real cost of advanced cancer treatment

The cost of CAR T-cell therapy is a major challenge for health systems. In the United States, which acts as the "anchor" for global pricing, these treatments are very expensive. Because many other countries look at U.S. prices to set their own, the high starting cost makes it difficult for nations with smaller budgets to provide the treatment to their citizens.

The high price tag comes from several factors:

• Business decisions: Sometimes, pharma companies only apply for funding in certain countries.
• High costs and setup: Building specialized labs and training the medical teams needed for this therapy are very expensive.
• Pricing rules: Many countries set their prices based on what others are paying. 

Solutions for better healthcare access

While access to CAR-T is currently not universal, there are ways to improve. One promising proposal is the rise of "academic" programs. In countries like Spain, India, and Brazil, universities and hospitals are trying to produce their own CAR T cells locally. These models can reduce costs and shorten the time needed to make the treatment. While these programs are still small and must follow strict safety rules, they might be the best way for countries with limited resources to offer this technology to more people.

CAR T-cell therapy is a great option for those who have access to it, but its reach is currently limited. The high cost of manufacturing and the way global prices are set make it hard for many health systems to keep up. By exploring new ways to produce these treatments locally, the medical community can work toward a future in which a person's location no longer determines their chance of accessing the treatments they need.

Don’t miss HealthTree news, events and programs with our Newsletter. 

SUBSCRIBE TO NEWSLETTER 

Source: Access to CAR T-cell therapy across diverse global markets